Antibody response to SARS-CoV-2 mRNA vaccines in pregnant women and their neonates

  1. Malavika Prabhu
  2. Elisabeth A. Murphy
  3. Ashley C. Sukhu
  4. Jim Yee
  5. Sunidhi Singh
  6. Dorothy Eng
  7. Zhen Zhao
  8. Laura E. Riley
  9. Yawei J. Yang

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

Pregnant women were excluded from initial clinical trials for COVID-19 vaccines 1–2 , thus the immunologic response to vaccination in pregnancy and the transplacental transfer of maternal antibodies are just beginning to be studied 4–5 .

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2021.04.05.438524: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: The study was approved by the Weill Cornell Medicine institutional review board.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variableBetween January 28 and March 31, 2021, we studied 122 pregnant women and their neonates at time of birth.

    Table 2: Resources

    Antibodies
    SentencesResources
    Semi-quantitative testing for antibodies against S-Receptor Binding Domain (RBD) (ET HealthCare)3 was performed on sera of maternal peripheral blood and neonatal cord blood at the time of delivery to identify antibodies mounted against the vaccine.
    antibodies against S-Receptor Binding Domain (RBD
    suggested: None
    All women tested negative for antibodies against the Nucleocapsid Protein (NP) antigen (Roche Diagnostics EUA) to ensure that the antibodies detected were not produced in response to past SARS-CoV-2 infection.
    antibodies against the Nucleocapsid Protein (NP)
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2021.04.05.438524 on bioRxiv